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Abstract
Background: Neuroinflammation and blood-brain barrier (BBB) disruption are common features of many brain
disorders, including Alzheimer’s disease, epilepsy, and motor neuron disease. Inflammation is thought to be a driver
of BBB breakdown, but the underlying mechanisms for this are unclear. Brain pericytes are critical cells for
maintaining the BBB and are immunologically active. We sought to test the hypothesis that inflammation regulates
the BBB by altering pericyte biology.
Methods: We exposed primary adult human brain pericytes to chronic interferon-gamma (IFNγ) for 4 days and
measured associated functional aspects of pericyte biology. Specifically, we examined the influence of inflammation
on platelet-derived growth factor receptor-beta (PDGFRβ) expression and signalling, as well as pericyte proliferation
and migration by qRT-PCR, immunocytochemistry, flow cytometry, and western blotting.
Results: Chronic IFNγ treatment had marked effects on pericyte biology most notably through the PDGFRβ, by
enhancing agonist (PDGF-BB)-induced receptor phosphorylation, internalization, and subsequent degradation.
Functionally, chronic IFNγ prevented PDGF-BB-mediated pericyte proliferation and migration.
Conclusions: Because PDGFRβ is critical for pericyte function and its removal leads to BBB leakage, our results
pinpoint a mechanism linking chronic brain inflammation to BBB dysfunction.
Keywords: Inflammation, Blood-brain barrier, Proliferation, Migration
Background
Inflammation and disruption of the blood-brain barrier
(BBB) are present in virtually all neurodegenerative dis-
eases, as well as epilepsy, stroke, and traumatic brain injury
[1–4]. In Alzheimer’s disease (AD), Huntington’s disease,
and Parkinson’s disease (PD), neuroinflammation appears
to be an early event in disease progression [5–7]. Most
notably, the risk of AD is significantly increased following
episodes of an acute inflammatory insult such as infection
or with chronic inflammatory conditions such as diabetes
[4, 8–11]. Furthermore, inflammation in models of AD,
multiple sclerosis (MS), and stroke can induce BBB damage
and hence exacerbate and even precede neuropathology
[12–14]. In the case of amyotrophic lateral sclerosis, several
studies have now shown that blood-spinal cord barrier
(BSCB) dysfunction precedes motor neuron damage, and
therefore, both the BBB and BSCB have been posed as a
potential therapeutic target for early treatment [15, 16].
Furthermore, reparation of the BSCB in a model of motor
neuron disease slows disease progression [17].
Therefore, current evidence suggests that inflamma-
tion and loss of BBB and BSCB integrity may contribute
to disease development as opposed to being a conse-
quence of existing neuropathology [18, 19].
The neurovascular unit is a key functional component of
the BBB that is made up of closely connected endothelial
cells, pericytes, glia, and neurons [20]. Although previous
attention has been focused on other cell types, the scientific
community is developing a new appreciation for brain peri-
cytes and their role in neuroinflammatory processes [21].
Brain pericytes can respond to inflammatory signals such
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as circulating cytokines and convey this information to sur-
rounding cells by way of chemokine and cytokine secretion
[22–26]. However, pericytes are also vital to BBB function
as a reduction in pericyte coverage causes vascular and bar-
rier defects [27]. In diseases such as diabetic retinopathy,
and amyotrophic lateral sclerosis, BBB and BSCB impair-
ment has been linked to pericyte deficiency, while in
human AD, BBB impairment is directly correlated with the
degree of pericyte dysfunction [28–31]. The coinciding
presence of inflammation, BBB breakdown, and pericyte
loss in brain disease indicates that inflammation may be
one of the drivers of BBB and BSCB leakiness. Although
the mechanism for this is not currently understood, we
propose that inflammation modulates pericytes specifically
and therefore alters the condition of the BBB/BSCB.
One potential mechanism might be the regulation of
signalling through the platelet-derived growth factor
receptor-beta (PDGFRβ). This is a well-known receptor
tyrosine kinase, commonly used as a marker for peri-
cytes, and is crucial to the regulation of survival, prolif-
eration, and migration signals of pericytes [32]. In the
central nervous system (CNS), homodimers of platelet-
derived growth factor beta subunit (PDGF-BB) are
secreted by endothelial cells and bind PDGFRβ on the
cell surface of pericytes to promote pericyte vascular
coverage in the BBB [33, 34]. Examination of pericyte-
deficient animals has revealed that the PDGFRβ signal-
ling pathway is required for pericyte survival and conse-
quently BBB development as well as proper function
during adulthood and ageing [27, 35]. Furthermore, pre-
vious studies have indicated that PDGFRβ signalling is
altered in response to inflammatory signals, although
this has not been investigated in human brain pericytes
[36, 37].
Since inflammation, pericyte loss and subsequent BBB
impairment are widespread in neurodegenerative disor-
ders, identifying how inflammation may modulate pericyte
function, and therefore contribute to pathology is of great
importance. To study these processes in vitro, we used a
model of chronic interferon-gamma (IFNγ)-mediated in-
flammation and investigated its effects on human brain
pericytes [36]. IFNγ is a central component of the inflam-
matory response in the CNS and can be secreted by
microglia, astrocytes, and endothelial cells as well as circu-
lating immune cells [38–42]. This classical inflammatory
mediator has been implicated in AD, PD, autoimmune
disease, and BBB disruption and provided a suitable sys-
tem to model a chronic CNS inflammatory environment
and its effects on human brain pericytes [41, 43, 44].
Methods
Biopsy of human brain tissue
Human brain tissue from both male and female patients
was obtained from biopsy at Auckland City Hospital
following surgery for intractable temporal lobe epilepsy and
approved by the Northern Regional Ethics Committee.
Human brain cell isolation from epilepsy tissue
Isolation of pericytes from human brain tissue was carried
out as previously described [22, 23]. Cells were seeded at
1.0 × 106 for T75 flasks or plated at a density specifically
optimized for each set of experiments as detailed below.
Cells were cryopreserved in FBS with 5 % dimethyl sulfox-
ide (DMSO) at a density of 1.0 × 106 cells/mL.
Cell treatments
Model of chronic inflammation
Pericytes were seeded at 3.0 × 103 cells/well or 1.3 × 105
cells/well in either 96-well (for immunocytochemistry)
or 6-well plates (for western blot or RNA extraction) in
complete media (DMEM/F12 with 10 % FBS and 1 %
PSG (penicillin 100 U/ml, streptomycin 100 μg/ml, L-
glutamine 0.29 mg/ml)). After 24–48 h of culture, media
was replaced with vehicle (0.1 % bovine serum albumin
(BSA) in PBS) or IFNγ (R&D Systems (Minneapolis, MN,
USA) 285-1F), each diluted 1/100 into cell culture media
for a final concentration of 1 ng/mL. Cells were treated
every 24 h for a total of 4 days. Twenty-four hours after
the fourth treatment, cells were serum starved for 2 h to
bring phosphorylation levels to baseline and then treated
with vehicle (0.1 % BSA in 4 mM HCl) or PDGF-BB
(R&D Systems 220-BB,) diluted 1/100 in cell culture
media (final concentration of PDGF-BB was 100 ng/mL)
for 30 min. Phosphorylated and total protein expression
was measured by western blot, or protein expression and
distribution were analysed by immunocytochemistry.
Alternatively, for longer treatments (such as proliferation
and migration assays), PDGF-BB (10 ng/mL) was used.
Immunocytochemistry
At endpoint, pericytes were fixed using 4 % paraformalde-
hyde solution. After cells were washed and permeabilized
in PBS with 0.2 % Triton X-100™ (PBS-T), they were
incubated with primary antibodies overnight at 4 °C (all
antibodies were diluted in goat immunobuffer (1 % goat
serum, 0.2 % Triton X-100™, and 0.04 % thiomersal in
PBS)). Dilutions and sources of antibodies are listed in
Table 1. Plates were washed again in PBS-T, incubated
with secondary antibodies for 2–3 h at room temperature,
and then rinsed. Nuclei were detected using Hoechst
(33258 Sigma, St. Louise, MO, USA).
Acquisition and analysis of immunocytochemistry images
Image acquisition was done using the ImageXpress micro
XLS™ (Molecular Devices) high-content screening system,
housed at the Biomedical Imaging Research Unit, University
of Auckland [45]. Images were acquired from micro-well
plates using the ×10/0.3 Plan or ×20/0.45 NA CFI Super
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Plan Fluor ELWD ADM objective lens and Lumencor Spec-
tra X configurable light engine source. Excitation and emis-
sion filters used are listed in Table 2.
High-content analysis was then performed with
MetaXpress™ version 5.3.04 (Molecular Devices) analysis
software. Several algorithms were used to analyse im-
munocytochemical data including:
Count nuclei: Cells were counted as positive for
Hoechst based on specific user-defined parameters.
These parameters included approximate minimum
and maximum width (μm) and intensity above local
background (grey levels). While intensity settings
had to be optimized between experimental plates,
the size range for positive cells remained constant.
Cells between 7 and 30 μm in width were counted
as positive, and this number was then used for total
cell counts in each well and site acquired.
Cell scoring/multi-wavelength cell scoring: These features
were used for quantification of Ki67 and EdU. Images were
acquired at ×20 magnification. Positive cells were those
associated with a nucleus (Hoechst-positive) and stained
positively for the protein of interest within user-defined set-
tings for intensity and size based on optimized filter set-
tings. Quantification of results were given as a percentage
of cells stained positively for the indicated antibody out of
the total number of cells as counted positive by Hoechst.
All data from proliferation assays were derived from tripli-
cate wells and nine sites per well.
Integrated intensity: In some cases where the intensity
of the stain was more indicative of overall protein
expression, as opposed to the number of cells
Table 1 Antibodies and dilutions used in this study
Company Catalogue number WB ICC
Primary antibodies
PDGFRβ rabbit monoclonal Cell Signaling 3169 1/1000 1/500
Phospho-PDGFRβ Tyr 751 rabbit monoclonal Cell Signaling C63G6 1/1000
PDGFRβ rabbit monoclonal Abcam 35270 1/500
αSMA mouse monoclonal Dako IS611 1/10 1/4
Akt mouse monoclonal Cell Signaling 2920 1/2000
Phospho-Akt S473 rabbit polyclonal Cell Signaling 9271 1/1000
Phospho-ERK mouse monoclonal Santa Cruz sc-7383 1/500
PDGF-BB rabbit polyclonal Abcam ab23914 1/800
ERK 1 (K-23) rabbit polyclonal Santa Cruz sc-94 rabbit 1/500
GAPDH mouse monoclonal Abcam ab9484 1/1500
CD140b (PDGFRβ-N-terminal) AbD Serotec 7460-3104 1/200
Ki67 rabbit polyclonal Dako A0047 1/500
aCD140b-PE BD Biosciences 558821 1/5
Secondary antibodies
Goat anti-rabbit Alexa 488 Life Technologies A11034 1/500
Goat anti-mouse Alexa 594 Life Technologies A11032 1/500
Goat anti-mouse IRDye-680LT LiCOR 926-68020 1/10000
Goat anti-rabbit IRDye-800CW LiCOR 926-32211 1/10000
All antibodies used in this study are listed with the company of origin, the method (WB western blot, ICC immunocytochemistry), and the dilution used
aUsed for flow cytometry
Table 2 Excitation and emission parameters for ImageXpress micro XLS™ high content screening system
Cube Filters Lumencor light engine Ex range Ex peak Dichroic Em range Em peak
Triple 4 DAPI UV (380–410) 381–399 390/18 436 445–469 457
Triple 4 FITC Cyan (460–490) 484–504 494/20 514 518–542 530
Triple 4 TRED Green (535–600) 561–590 575/25 604 612–643 628
Quad 5 DAPI UV (380–410) 381–399 390/18 410 419–460 440
Quad 5 FITC Cyan (460–490) 474–496 485/20 504 507/533 521
Quad 5 CY5 Red (620–750) 644–656 650/13 669 675–723 700
Microscope information for all image acquisition in this study including light source, filters, excitation, and emission range and peaks in nanometer
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expressing the protein above a given threshold level, it
was more appropriate to quantify the integrated
intensity of the stain. The integrated intensity per cell
as presented in the text is calculated as previously
described [46]. Briefly, a user-defined threshold is set
for the intensity of the pixels above background levels
and below brightly labelled debris. Parameters for size
are also incorporated into this analysis to identify
positive cells. The integrated intensity for the staining
of interest is then calculated by subtracting the
background noise from these values and excluding the
debris. This number incorporates both the number of
pixels above background, and intensity of those pixels
minus background, in addition to the total cell number
(as counted by Hoechst-positive cells).
Transfluor assay: This algorithm is designed to count
and measure localized granules or puncta and is
derived from the granularity assay used previously [46].
Settings were optimized to detect small puncta of
PDGFRβ staining within a user-defined size range and
intensity above local background. Total number of
puncta in an image was then normalized to total cell
number (Hoechst).
For each set of analysis, settings were optimized for
each antibody label and parameters were tested on at
least four randomly selected images from each plate to
ensure quantitation was a representative of actual stain-
ing. Internal controls were used to ensure basal settings
were consistent between repeated experiments. The pa-
rameters set are then applied to all images in a sequence
(from a single plate), so that comparisons can be made
within an experimental plate. Data is presented from
the average of those four images from each replicate
well. For all experiments presented here, treatment
conditions were done in triplicate, except for the migra-
tion assays which had six replicates per condition, per
experiment.
Quantitative RT-PCR
Quantitative reverse transcriptase polymerase chain reac-
tion (qRT-PCR) was performed for Fig. 1 as described
previously [22, 47]. Alternatively, for Fig. 7, RNA was ex-
tracted using the RNAqueous® micro-total RNA isolation
kit (Ambion (CA), Life Technologies). cDNA was made
from 1.5 μg DNase-1 (Promega)-treated RNA using the
Superscript III first-strand synthesis kits (Invitrogen). qRT-
PCR was performed using Platinum SYBR Green qPCR
SuperMix-UDG with Rox kit (Invitrogen). The level of gene
expression was normalized to glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) at time zero or untreated condi-
tions using the ΔCt method [48]. The list of primers used is
included in Table 3.
Confocal microscopy
Cells were seeded directly onto #1.5 glass coverslips
(Menzel Gläser) in 48-well plates. Twenty-four hours
later, cells were treated as above for the chronic cytokine
model. After 96 h, cells were serum starved for 2 h and
then treated with PDGF-BB (100 ng/mL) or vehicle for
30 min to internalize PDGFRβ. Cells were then fixed
with 4 % PFA and processed as above for immunocyto-
chemistry with a PDGFRβ antibody and Hoechst. Cover-
slips were mounted onto slides using Dako fluorescent
mounting media. All confocal images were recorded
using a Zeiss LSM710 inverted confocal microscope with
a ×63 oil immersion lens (NA 1.4) at 0.32-μm slices.
Orthogonal projections were generated using the Fiji
plugin for ImageJ software version 1.47k from the
National Institute of Health (NIH).
Live labelling of plasma membrane PDGFRβ
Membrane PDGFRβ was detected using live labelling as
previously described with modifications [49]. At endpoint,
plated cells were taken onto ice for 90 s, media was re-
moved, and cells were washed with serum-free DMEM/
F12 with 5 mg/mL BSA (SFM/BSA). Antibody against the
extracellular N-terminus of PDGFRβ (CD140b) was di-
luted 1/200 into SFM/BSA and added to desired wells.
The plate was then incubated at room temperature for
30 min. Following antibody incubation, cells were washed
in SFM/BSA, fixed with 4 % PFA for 15 min, and perme-
abilized with PBS-T for 20 min. Co-labelling and image
acquisition was then performed as above.
Flow cytometry for cell surface PDGFRβ
At endpoint, cells were washed in PBS, incubated with
Accutase (A1110501 ThermoFisher) at 37 °C for 5 min,
and gently triturated to produce a single-cell suspension.
An equal volume of complete media was added to stop
enzymatic activity, and cells were centrifuged at 160×g
for 5 min. The supernatant was discarded, and cells were
resuspended in FACS buffer (1 % FBS in PBS). Cells
were incubated with 7-aminoactinomycin (7-AAD) (1:20
dilution; 51-68981E, BD Biosciences CA, USA) and
CD140b-PE (1:5 dilution; PE mouse anti-human
CD140b-PE 558821, BD Biosciences) for 15 min on ice.
Cells were centrifuged at 160×g for 5 min at 4 °C, the
supernatant was discarded, and cells were resuspended
in FACS buffer. Samples were run on an Accuri C6 flow
cytometer (BD Biosciences), and 8000 viable cells were
gated based on forward and side scatter and 7-AAD ex-
clusion. Analysis of flow cytometry data was performed
using FlowJo software (v 7.6.5). Mean fluorescence in-
tensity of CD140b cell surface expression was deter-
mined from three independent cases.
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Cell proliferation, viability, and migration assays
To measure PDGF-BB-induced cell growth, pericytes were
cultured and treated as above for the chronic inflamma-
tion model with additional treatments outlined below.
Cell proliferation assay
After 48 h of cytokine treatment, either vehicle (0.1 %
BSA in 4 mM HCl) or PDGF-BB diluted 1/100 was
added to measure PDGF-BB-induced cell proliferation
(final concentration of PDGF-BB was 10 ng/mL).
Proliferation was measured by 5-ethynyl-2′-deoxyuridin
(EdU) with Click-iT®Assay Kit (Life Technologies
C10340) according to the manufacturer’s instructions
and Ki67 immunocytochemical labelling. Briefly, EdU
(5 μM) was added 24 h prior to endpoint and cells incu-
bated for a further 24 h. Cells were fixed with 4 % PFA
Fig. 1 Chronic IFNγ treatment alters αSMA, but not PDGFRβ expression, or cell number in human brain pericytes. a Pericytes were treated for
four consecutive days (once every 24 h) with either vehicle (Veh) or IFNγ (1 ng/mL) as depicted. b, c Cells were then fixed and imaged under
brightfield (b), and total cells counted from Hoechst labelled nuclei (c). d–g Representative images and quantification of PDGFRβ (green) (d, e), or
αSMA (red) (f, g) overlaid with Hoechst. Scale bar, 100 μm. The integrated intensity of the staining was normalized to cell number (Hoechst) (c)
and vehicle conditions, quantified from triplicate wells, and plotted as mean ± s.e.m. (n = 3) and ****(p < 0.0001) (Student’s t test). h, i mRNA from
pericytes treated as in a was analysed by qRT-PCR. Inflammatory target gene (IP-10, MCP-1, COX2, ICAM-1, CD74) (h) and pericyte marker and prolif-
eration marker gene (PDGFRβ, αSMA and Ki67) (i) expression was normalized to GAPDH and plotted as a mean fold change from vehicle (set to 1)
(2^ΔΔCT) ± s.e.m. (n = 3), **(p < 0.01) by a Mann-Whitney, non-parametric test of ΔCT values
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for 15 min at room temperature. Cells were rinsed with
3 % BSA in PBS and then permeabilized with 0.5 %
Triton X-100 in PBS for 20 min at room temperature.
Cells were washed twice with 3 % BSA in PBS, and then,
EdU reaction cocktail was added for 30 min at room
temperature protected from light. Cells were then washed
once more with 3 % BSA in PBS and labelled with a Ki67
antibody as described above for immunocytochemistry.
AlamarBlue® assay
AlamarBlue® (AbD Serotec BUF012B) was used as a meas-
ure of cell health and metabolism. The AlamarBlue® re-
agent is an oxidation-reduction indicator that produces
fluorescence when reduced by media metabolizing cells.
AlamarBlue® reagent was added to wells treated as above
at a 1/10 dilution, and cells were incubated at 37 °C, 5 %
CO2 for 1 h prior to endpoint of experiment. Fluorescence
was measured using the FLUOStar Optima plate reader
(BMG LABTECH) with an excitation of 544 nm and
emission of 590 nm. Controls of media alone (no cells)
with AlamarBlue® were included, and fluorescence values
were used as baseline. Data are presented as mean % Ala-
marBlue® metabolized per cell and normalized to vehicle
controls ± standard error of the mean (s.e.m.).
LDH assay
Lactate dehydrogenase (LDH) assay (Roche) was
performed as per manufacturer’s instructions. Briefly, at
endpoint, cell media from experimental wells as well as
controls (cells lysed with Triton X-100™ to obtain 100 %
lysis) was transferred to a new cell culture plate and cen-
trifuged at 250×g. The supernatant was transferred to a
new cell culture plate containing an equal volume of
LDH reagent mix and incubated in the dark for 30 min
at room temperature. Absorbance was measured at
492 nm from triplicate wells and three cases. Data were
normalized to 100 % lysed wells and plotted as mean ±
s.e.m.
Migration assay
Cells were treated as above for proliferation assay. At
the 48-h time point, cells were scratched down the mid-
dle of the well with a sterile p200 pipette tip. Cells were
washed with complete media to remove unattached deb-
ris, and media containing vehicle, or PDGF-BB, diluted
1/100 was added to wells for a further 48 h (final con-
centration was 10 ng/mL). Chronic cytokine treatment
was continued every 24 h for a total of 96 h. Cells were
then rinsed and fixed with 4 % PFA for 15 min. Cells
were stained by adding Coomassie Blue (0.25 %) in 40 %
ethanol and 10 % acetic acid for 30 min at room
temperature. Stain was removed, and wells were allowed
to dry. Images were acquired as above for immunocyto-
chemistry with modifications; wells were acquired using
bright field at ×4 magnification to obtain the scratch
area. Cells that had migrated into the scratch area were
quantified manually using ImageJ version 1.47k from
NIH, using the Cell Counter plugin [50]. Each experi-
ment was counted by two individuals blinded to treat-
ment conditions.
Table 3 The list of primers used for qRT-PCR in this study
Accession number Gene Sequence Amplicon length
NM_002046.4 GAPDH (h) Fw CATGAGAAGTATGACAACAGCCT 113 bp
Rv AGTCCTTCCACGATACCAAAGT
NM_001565.3 IP-10 (CXCL10) Fw TGGCACACTAGCCCCACGTT 88 bp
Rv TGCTGAGACTGGAGGTTCCTCTGC
NM_002982.3 MCP-1 (CCL2) Fw CAGCCAGATGCAATCAATGCC 190 bp
Rv TGGAATCCTGAACCCACTTCT
NM_000963.2 COX2 (PTGS2) Fw AGGGTTGCTGGTGGTAGGAA 76 bp
Rv TCTGCCTGCTCTGGTCAATG
NM_000201.2 ICAM1 (h) Fw GAACCAGAGCCAGGAGACAC 84 bp
Rv GAGACCTCTGGCTTCGTCAG
NM_001025159.2 CD74 Fw GAGTCACTGGAACTGGAGGAC 81 bp
Rv CTGCTCTCACATGGGGACTG
NM_002609.3 PDGFRβ Fw CGCAAAGAAAGTGGGCGGCT 101 bp
Rv TGCAGGATGGAGCGGATGTGGT
NM_001141945.2 αSMA Fw ACGTGGGTGACGAAGCACAGA 84 bp
Rv CGTCCCAGTTGGTGATGATGCC
NM_001145966.1 Ki67 Fw AGCGGAAGCTGGACGCAGAA 79 bp
Rv TCCAGGGGTTGGGCCTTTTCCT
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Western blotting
At endpoint, pericytes were rinsed with PBS and scraped
into Eppendorf tubes. Cells were centrifuged, and pellet
was resuspended in lysis buffer (25 mM Tris-HCl pH
7.5, 150 mM NaCl, 50 mM NaF, 0.5 mM EDTA pH 8,
0.5 % Triton-X 100™, 5 mM β-glycerophosphate, with
fresh 1 mM DTT, 1 mM PMSF, 1 mM Na3VO4). Of the
total protein, 20 % from one well of a six-well plate was
diluted 1:1 in 2× Laemmli buffer (125 mM Tris-HCl, pH
6.8, 5 % glycerol, 4 % sodium dodecyl sulphate (SDS),
0.2 % bromophenol blue) and separated on 4–12 % pre-
cast gels (Life Technologies) by SDS-polyacrylamide gel
electrophoresis.
Fluorescent westerns were carried out as previously
described [22]. Briefly, proteins were transferred to
polyvinylidene difluoride (PVDF) membranes (Millipore
(Billerica, MA, USA) IPFL00010 Immobilon-FL 0.45 mm)
for optimal fluorescence signal and blocked in Odyssey®
Blocking Buffer (Li-COR (NE, USA) 927-40000) diluted
1:1 in Tris-buffered saline with 0.1 % Tween®-20 (TBS-T),
for 1 h at room temperature. Membranes were incubated
with primary antibodies (Table 1) diluted in Odyssey®
Blocking Buffer and TBS-T (1:1) overnight at 4 °C. Mem-
branes were incubated with secondary antibodies (Li-
COR, Table 1) diluted in Odyssey® Blocking Buffer and
TBS-T (1:1) with 0.1 % Tween®-20 and 0.02 % SDS for 2 h
at room temperature. Images were captured using a Li-
COR Odyssey FC® imaging system, and band intensity was
quantified using Image Studio™ Lite (Ver 5.0). Fluorescent
images were converted to greyscale, and inverted using
Adobe Photoshop. Some proteins were analysed on paral-
lel blots to avoid the need to strip the membranes; how-
ever, all quantification was completed on intensities from
the same blots.
Statistical analysis
Each experiment was repeated on three individual cases,
i.e. pericytes from separate donors, and normalized data
were combined and presented as the mean ± s.e.m. unless
otherwise stated. GraphPad Prism (Ver 6) for Windows
was used for statistical analysis. Data were tested for nor-
mal distribution using D’Agostino and Pearson omnibus
test for normality. Data that were normally distributed
was then analysed with either two-tailed student’s t test or
one-way analysis of variance (ANOVA) with Dunnett’s
post hoc test for multiple comparisons. If data were not
normally distributed, then the non-parametic Kruskal-
Wallis test was used followed by Dunn’s multiple com-
parison tests to determine significance. Alternatively, for
qRT-PCR data, the Mann-Whitney rank-sum test was
used to analyse the ΔCT values. Two-way ANOVA was
used when comparing groups of independent variables,
with Tukey’s multiple comparison tests. Significance from
control conditions is indicated by *(p < 0.05), **(p < 0.01),
***(p < 0.001), and ****(p < 0.0001).
Results
Chronic IFNγ treatment modulates pericyte morphology
and phenotype
Pericytes exposed to IFNγ were analysed for their growth
and cell marker expression (Fig. 1a). IFNγ-treated cells ap-
peared to grow at a similar rate to vehicle-treated cells,
they adopted a more spread-out, flat, cobblestone-like pat-
tern (Fig. 1b), and total cell number was not changed after
4 days of IFNγ treatment (Fig. 1c).
The expression of pericyte markers PDGFRβ and alpha
smooth muscle actin (αSMA) were also examined by im-
munocytochemistry. Integrated intensity was used as a
measure of overall expression of either αSMA or PDGFRβ
staining employing a previously published algorithm [46].
IFNγ treatment did not significantly alter the expression
of PDGFRβ (Fig. 1d, e) but considerably reduced the stain-
ing intensity of αSMA (Fig. 1f, g). Consistent with previ-
ous reports of tumour necrosis factor alpha (TNFα) and
interleukin-1beta (IL-1β) treatment in pericytes, both
PDGFRβ and αSMA protein expression were reduced
after chronic treatment of either cytokine [51] (Additional
file 1: Figure S1).
We have previously shown that inflammatory cues
alter gene expression in human brain pericytes [22, 23].
Therefore, using gene hits obtained from a previous
microarray study [22], we examined gene expression
changes in pericytes under chronic IFNγ conditions.
Inflammatory response genes interferon-inducible protein-
10 (IP-10), monocyte chemotactic protein-1 (MCP-1), cy-
clooxygenase 2 (COX2), intracellular adhesion molecules
(ICAM-1), and cluster of differentiation (CD74) remained
elevated after 96 h of IFNγ treatment (Fig. 1h). We also
measured messenger RNA (mRNA) expression of PDGFRβ,
αSMA and Ki67 (Fig. 1i). Interestingly, although mRNA
data matched observations for protein levels of αSMA, we
saw a discrepancy in PDGFRβ mRNA and protein expres-
sion. Despite having seen no change at the protein level,
chronic IFNγ conditions caused a 1.5-fold increase in
PDGFRβ transcripts compared to controls, which was con-
sistent across three separate cases. In addition, there was a
consistent trend of a decrease in Ki67 after IFNγ treatment
which suggested an inhibitory effect on cell proliferation.
PDGFRβ signalling in adult human brain pericytes
PDGFRβ plays an important role in pericyte function.
We therefore first sought to determine the normal
physiological response of human brain pericytes to
PDGF-BB in the absence of IFNγ by measuring activa-
tion of downstream signalling proteins. Pericytes cul-
tured as previously described [22] were serum starved
for 2 h and then treated with vehicle or PDGF-BB
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(10 ng/mL) for 30 min up to 24 h. Tyrosine 751 (Tyr751)
is known to be the major residue of the PDGFRβ that is
phosphorylated in response to PDGF-BB stimulation and
responsible for association of the receptor with
phosphotidylinositol-3-kinase (PI3K) [52]. Thus, phos-
phorylation of PDGFRβ at Tyr751 was used as marker of
receptor activation. Activation of the PDGFRβ was de-
tected after 30 min of PDGF-BB treatment and gradually
decreased over the 24-h treatment time (Fig. 2a, b and
Additional file 2: Figure S2). This observation was consist-
ent with previous reports of commercial human brain
pericytes [53]. Examination of downstream pathway acti-
vation demonstrated elevated levels of phosphorylated
Akt and extracellular signal-regulated kinase (ERK) fol-
lowing PDGF-BB treatment, which was maintained up to
24 h (Fig. 2a, d, e) and was consistent with studies in other
cell types [54, 55]. In addition, levels of PDGFRβ declined
with exposure to the ligand (Fig. 2a, c), suggesting an
agonist-induced downregulation. We also detected ele-
vated levels of PDGF-BB in cell lysates, from 1–24 h
(Fig. 2a, f ). This is most likely due to the detection of ex-
ogenous PDGF-BB internalizing with the PDGFRβ.
Chronic IFNγ enhances PDGF-BB-induced PDGFRβ
phosphorylation and internalization
Since PDGFRβ plays such an important role in pericyte
survival, and previous work has shown cytokines to alter
PDGF signalling in other cell types [37, 51], we were in-
terested in whether chronic IFNγ could influence
PDGFRβ activation. Pericytes were treated with IFNγ for
4 days as described in the methods, and the PDGF-BB-
induced phosphorylation status of PDGFRβ (Tyr751)
was examined by western blot (Fig. 3a). As expected,
there was no detectable PDGFRβ phosphorylation under
serum-starved vehicle-treated conditions. Treatment
with PDGF-BB (100 ng/mL) for 30 min induced phos-
phorylation of PDGFRβ at Tyr751 (Fig. 3b). Interest-
ingly, the phosphorylation of PDGFRβ in response to
PDGF-BB was greater in pericytes chronically treated
with IFNγ than controls (Fig. 3b, c and Additional file 3:
Figure S3). Since it has been well-documented that
PDGFRβ activation can act through both the PI3K-Akt, as
well as mitogen-activated protein kinase (MAPK)-ERK
pathways [34, 56], we were interested in whether height-
ened PDGFRβ activation induced by IFNγ would also be
reflected in the downstream pathways. However, western
blot results did not indicate any changes with Akt or ERK
activation under the inflammatory conditions tested
(Fig. 3b, d, e and Additional file 3: Figure S3).
Characteristic PDGF signalling involves binding of the
ligand to the receptor, followed by dimerization, auto-
phosphorylation, and internalization [57]. Additionally, it
has been shown that PDGFRβ internalization can occur
independently of receptor phosphorylation [58]. We
Fig. 2 Human brain pericytes respond to PDGF-BB signals in vitro. a Pericytes were serum starved for 2 h, then treated with vehicle (lanes 1 and 7) or
PDGF-BB (100 ng/mL) (lanes 2–6, and 8) for the indicated times, and analysed by SDS-PAGE. Representative blots from three cases are shown. b Blots from
a were analysed and quantified with Image Studio™. Phosphorylated PDGFRβ (Tyr751) (p-PDGFRβ) (b), PDGFRβ (c), and PDGF-BB (f) were normalized to
GAPDH; phosphorylated Akt (Ser473) (p-Akt) (d) and phosphorylated ERK (Tyr204) (p-ERK) (e) were normalized to total Akt and ERK, respectively. **Bottom
band in pERK blot is GAPDH
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therefore examined PDGF-BB-induced receptor internal-
ization by immunocytochemistry. Upon close examin-
ation of PDGFRβ staining, we observed that PDGF-BB
treatment increased the number of puncta in the cell,
which is indicative of receptor internalization (Fig. 3f )
[37]. The number of puncta per cell was quantified using
the transfluor algorithm within the MetaXpress™ image
analysis software and normalized to vehicle-treated con-
trols (Fig. 3g). Treatment of pericytes with PDGF-BB
(100 ng/mL) for 30 min produced an increased number
of PDGFRβ puncta in control conditions. However, cells
treated chronically with IFNγ showed a marginal in-
crease in puncta per cell under basal (vehicle treated)
conditions, which was enhanced under ligand (PDGF-
BB)-stimulated conditions. This observation suggested
that IFNγ increased PDGF-BB-induced PDGFRβ intern-
alization. There was, however, no change in PDGFRβ
puncta with TNFα or IL-1β treatment in pericytes
(Additional file 4: Figure S4). We therefore focused our in-
vestigations on the mechanisms and outcomes of IFNγ-
induced changes in PDGFRβ signalling in pericytes.
In order to confirm that PDGFRβ puncta represented
internalized receptor, we performed confocal microscopy
on pericytes stimulated with vehicle or PDGF-BB for
30 min. Confocal analysis confirmed the localization of
the PDGFRβ puncta inside the cell (Fig. 3h).
Membrane PDGFRβ is increased by IFNγ treatment
We wondered whether the mechanism for enhanced
PDGF-BB-induced PDGFRβ internalization under
chronic IFNγ-treated conditions may involve IFNγ en-
hancing PDGF-BB production and therefore PDGFRβ
pathway activity. Western blot analysis of pericytes after
24 h of IFNγ treatment, however, did not show a detect-
able increase in PDGF-BB in the lysate (Fig. 4a, b). An-
other possible mechanism is that IFNγ may induce the
Fig. 3 Chronic IFNγ treatment increases PDGFRβ phosphorylation and internalization. a Pericytes were treated for four consecutive days (once
every 24 h) with either vehicle (Veh) or IFNγ (1 ng/mL). After 96 h total treatment, cells were serum starved for 2 h and then treated with vehicle
(−) or PDGF-BB (100 ng/mL) for 30 min as depicted. b Representative western blots of treated pericytes (n = 3). c–e Bands were quantified with
Image Studio™ and normalized to vehicle control. p-PDGFRβ (c) was normalized to total PDGFRβ, and p-Akt (d) and p-ERK (e) were normalized to
total Akt and ERK, respectively. f Representative images of pericytes treated as in a showing PDGFRβ (green) and Hoechst (blue), scale bar, 10 μm.
g PDGFRβ puncta in f were quantified using MetaXpress™ software and normalized to cell number and vehicle control and plotted as mean ±
s.e.m. (n = 3), ****(p < 0.0001), ###(p < 0.001), *(p < 0.05) (two-way ANOVA). h Cellular localization of PDGFRβ (green) and nuclei (blue) in pericytes
treated with vehicle (Veh) or PDGF-BB (100 ng/mL) for 30 min as above using confocal microscopy. Scale bar, 5 μm
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Fig. 4 Chronic IFNγ increases PDGFRβ membrane expression. a, b Detection of PDGF-BB in pericyte conditioned media. Human brain pericytes at
90 % confluence were left untreated (control (Con)) or serum starved for 2 h and then treated with vehicle, IFNγ (1 ng/mL), PDGF-BB (100 ng/mL), or
both IFNγ and PDGF-BB for 24 h. Lysates were collected for western blot analysis with the indicated antibodies, and a representative blot is shown
(n = 2) (a) Bands were quantified with Image Studio™ software and intensity was normalized to vehicle control (b); PDGF-BB was normalized to GAPDH.
c–e Pericytes were treated for 0, 24, 48, 72, or 96 h (more cytokines added once every 24 h to appropriate wells) with vehicle (Veh) or IFNγ (1 ng/mL).
c Grey value intensities of PDGFRβ membrane staining are depicted in a pseudo-colour image according to the legend (right). d Representa-
tive images of membrane PDGFRβ (red) and Hoechst (blue) in pericytes after 96 h of vehicle or IFNγ treatment. Scale bar, 100 μm. e Quantifi-
cation of total PDGFRβ (white bars) and membrane PDGFRβ (black bars) staining intensity per cell was normalized to 0 h time point, plotted as mean
± s.e.m. (n = 3), ****(p < 0.0001), ***(p < 0.001), **(p < 0.01) (ANOVA). f, g Pericytes were treated for four consecutive days (once every 24 h) with either
vehicle (Veh) or IFNγ (1 ng/mL). After 96 h total treatment, cells were serum starved for 2 h and then treated with vehicle (Veh) or PDGF-BB (100 ng/
mL) for 30 min. Surface PDGFRβ expression was analysed using flow cytometry, and a representative plot is shown (f). Mean fluorescence
intensity (MFI) of cell surface PDGFRβ is plotted as mean ± s.e.m. (n = 3) (g)
Jansson et al. Journal of Neuroinflammation  (2016) 13:249 Page 10 of 19
recruitment of PDGFRβ to the cell surface and thus in-
crease the ligand-accessible membrane pool. To address
this possibility, we performed live labelling of PDGFRβ to
detect membrane bound PDGFRβ and compared this with
total staining of permeabilized cells. Interestingly, there
was a more extensive increase in cell surface expression of
PDGFRβ under chronic IFNγ treatment, and this contin-
ued from 24 to 72 h (Fig. 4c). Observations of the pattern
of PDGFRβ membrane staining also showed an increase
after 96 h of IFNγ treatment (Fig. 4d). Quantification of
the staining intensity of membrane versus total PDGFRβ
expression was consistent with an increase of membrane
PDGFRβ over time with IFNγ treatment (Fig. 4e). In con-
trast, TNFα and IL-1β treatment decreased both total and
membrane PDGFRβ expression over time in a similar
manner (Additional file 5: Figure S5), indicating that the
re-distribution of PDGFRβ to the cell surface was specific
to IFNγ and not a general pro-inflammatory response.
Flow cytometry analysis of membrane PDGFRβ con-
firmed immunocytochemistry data. Pericytes treated for
30 min with PDGF-BB showed less surface PDGFRβ, a
result consistent with internalization of the receptor
(Fig. 4f, g). Furthermore, surface PDGFRβ detection by
flow cytometry was increased when pericytes were pre-
treated for 48 h with IFNγ. Ligand-stimulated internal-
ization of PDGFRβ in the presence of IFNγ was retained
as demonstrated by similar reduction in surface PDGFRβ
detection following PDGF-BB treatment. Thus, chronic
IFNγ increases the membrane-bound pool of the
PDGFRβ and therefore the amount of receptor available
for stimulation with the PDGF-BB ligand.
IFNγ blocks PDGF-BB-dependent pericyte proliferation
The importance of PDGF-BB-dependent signalling for
pericyte proliferation and migration in the formation of
new blood vessels of the BBB has been well-documented
in animal models [33]. However, it is currently unknown
what role PDGFRβ plays in adult human brain pericytes
and how these particular cells may be affected by a pro-
inflammatory environment. Past observations of
cytokine effects on PDGF-induced proliferation and mi-
gration have been conflicting depending on the cell types
studied [56]. We therefore analysed PDGF-BB-induced
cell proliferation in human brain pericytes (Fig. 5a).
Under vehicle pre-treated conditions, we observed an in-
crease in both Ki67 (Fig. 5b)- and EdU (Fig. 5c)-positive
cells, as well an increase in total pericyte counts after
48 h of PDGF-BB treatment (Fig. 5d). However, when
these parameters were measured under chronic IFNγ
conditions, there was a dramatic blunted proliferative re-
sponse to PDGF-BB when measured by either Ki67- or
EdU-positive cells or total cells (Fig. 5b–d). The ob-
served decrease in proliferation did not appear to be re-
lated to cell metabolism or cell death as measured by
AlamarBlue® or LDH, respectively, as this was un-
changed in PDGF-BB compared to vehicle controls
(Fig. 5e, f ). However, there was a significant decrease in
cell metabolism with IFNγ treatment that was not
dependent on PDGF-BB (Fig. 5f ). Thus, chronic IFNγ
decreases cell metabolism and blocks PDGF-BB-
dependent proliferative effects in human brain pericytes.
Alternatively, TNFα or IL-1β treatment did not signifi-
cantly alter PDGF-BB-induced proliferation in pericytes
(Additional file 6: Figure S6).
To determine whether PDGFRβ is responsible for the
proliferative action of PDGF-BB on human brain peri-
cytes, we used small interfering RNA (siRNA) to knock-
down receptor expression (Fig. 5g). PDGFRβ siRNA
reduced PDGFRβ expression to ≤5 % in human brain
pericytes without affecting cell number (Fig. 5h, i).
Knockdown of PDGFRβ dramatically inhibited PDGF-
BB-induced Akt phosphorylation (Fig. 5j). Reduction in
PDGFRβ expression also resulted in markedly reduced
proliferation in response to PDGF-BB stimulation simi-
lar to IFNγ treatment conditions as measured by Ki67,
EdU, and total cell counts (Fig. 5k, l, m). These com-
bined data indicate that PDGFRβ mediates the PDGF-
BB-induced proliferation response in human brain peri-
cytes and suggests that IFNγ is acting through inhibition
of the PDGF signalling pathway to block cell prolifera-
tion signals. Interestingly, we did not detect any loss of
viability of human brain pericytes depleted of PDGFRβ
in contrast to animal knockout studies [35] (Fig. 5m).
Migration of human brain pericytes is blocked by IFNγ
To further study the actions of IFNγ on human brain peri-
cytes, we investigated pericyte migration, which is an im-
portant property of these cells [33, 53]. We assessed the
ability of pericytes to migrate in a scratch wound assay
(refer to Fig. 6a). After 48 h of PDGF-BB treatment, we
detected an increase in migration of pericytes into the
wound area compared to controls (Fig. 6a, b). In congru-
ence with proliferation data, under chronic IFNγ condi-
tions, PDGF-induced movement of pericytes into the
wound area was greatly reduced. However, in contrast to
the effect on proliferation, IFNγ also caused a significant
inhibition of migration in the absence of PDGF-BB treat-
ment. These data would indicate that IFNγ can modulate
pericyte function by both PDGF-dependent and independ-
ent means. Closer observations of morphology of migrat-
ing cells demonstrated that under control conditions,
pericytes were elongated and extended out towards the
gap area, whereas when exposed to IFNγ, cells adapted a
more polygonal-like structure (Fig. 6c).
IFNγ inhibits PDGF-BB-induced PDGFRβ re-expression
Although our results from proliferation and migration
assays were consistent with previous reports of cell
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Fig. 5 Chronic IFNγ treatment and PDGFRβ knockdown blocks PDGF-BB-induced proliferation in pericytes. a Pericytes were treated for four consecutive
days (once every 24 h) with either vehicle (Veh) or IFNγ (1 ng/mL). b, c After 48 h of cytokine treatment, cells were treated with either vehicle or PDGF-BB
(10 ng/mL) to measure the PDGF-induced proliferative response. This was done in two ways: after 96 h total treatment, cells were fixed, labelled with a
Ki67 antibody and Hoechst (b); alternatively, EdU was added to measure cell proliferation over the final 24 h of the experiment (c). Positive cells of the total
cells measured by Hoechst (d) were quantified and plotted as mean ± s.e.m. (n= 3), ****, ####(p< 0.0001), ***(p< 0.001), *(p< 0.05) from a two-way ANOVA.
e, f LDH release (e) and AlamarBlue reduction (f) were also measured as cell death and cell health outputs, respectively, from the above proliferation
experiments. g Knockdown of PDGFRβ in pericytes with siRNA after 96 h immunolabelled for PDGFRβ (green) and Hoechst (blue), scale bar, 100 μm. h, i
Quantification of pericytes positive for PDGFRβ after siRNA knockdown. Percent positive for PDGFRβ (h) of the total cells measured by Hoechst (i), mean
(per well) ± s.e.m. (n= 1). j Representative western blot of PDGF-BB response in PDGFRβ deficient pericytes (n= 2). k–m Proliferation response to PDGF-BB
in PDGFRβ deficient pericytes after 48 h. Ki67 (k), EdU (l) positive, and total cells (m) mean ± s.e.m. (n= 5) were plotted and analysed with two-way ANOVA,
****(p< 0.0001), ###(p< 0.001), ***(p< 0.001), and *(p< 0.05)
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growth inhibition by IFNγ, the increase in PDGFRβ
membrane expression, phosphorylation, and internaliza-
tion was not consistent with this effect. It has been doc-
umented in the literature that receptor internalization
can be used by the cell as a regulatory mechanism to
switch off a particular pathway, and avoid chronic signal
activation; indeed, this has been observed for PDGFRβ
pathway regulation [59]. Following internalization, re-
ceptor tyrosine kinases are known to recycle back to the
cell surface or to be degraded, each promoting distinct
cellular outputs. The predominant method of PDGFRβ
regulation is through receptor ubiquitination and subse-
quent degradation by lysosomes and proteasomes [60].
As shown in Fig. 2b, levels of PDGFRβ declined signifi-
cantly with exposure to the PDGF-BB (maximally at
24 h after ligand addition), suggesting that this mechan-
ism of receptor degradation might also be operating in
human brain pericytes. Hence, it was possible that des-
pite increasing cell surface expression of PDGFRβ,
chronic IFNγ treatment had a negative influence on sig-
nalling outputs by promoting the internalization and
degradation of PDGFRβ after ligand stimulation.
We therefore examined PDGFRβ expression by im-
munocytochemistry under chronic IFNγ conditions with
or without 48 h PDGF-BB treatment (Fig. 7a). Quantifi-
cation of PDGFRβ staining had shown a reduction in
protein expression upon treatment with PDGF-BB for
48 h, which is consistent with degradation of the recep-
tor (Fig. 7b) and our previous observations (Fig. 2b).
Chronic IFNγ treatment caused an even further reduc-
tion in PDGFRβ protein levels following PDGF-BB
stimulation. There was also a significant reduction in
αSMA expression in response to PDGF-BB as well as
the previously observed effect of IFNγ treatment
(Fig. 7c). Interestingly, PDGF-BB did not affect αSMA
expression under chronic IFNγ conditions.
Closer examination of the cycling pattern of PDGFRβ
by western blot showed a reduction in total PDGFRβ
protein after 24 h of PDGF-BB treatment that was par-
tially recovered after 48 h (Fig. 7d–f ). However, recovery
of PDGFRβ expression was not seen in the presence of
IFNγ. Furthermore, analysis of αSMA expression dem-
onstrated a PDGF-independent reduction with IFNγ
treatment that was consistent across three cases and
Fig. 6 IFNγ blocks pericyte migration independently of PDGF-BB. a, b Cell migration was measured by scratching wells after 48 h of IFNγ (1 ng/mL) treatment
and measuring the number of cells that moved into the gap area after a further 48 h with vehicle or PDGF-BB (10 ng/mL) treatment. Representative images
of Coomassie-stained pericytes are presented in a, and manual counts of cells in the gap area (normalized to vehicle-treated condition), plotted as mean±
s.e.m. (n= 3) ####, ****(p< 0.0001), **(p< 0.01), (two-way ANOVA), are presented in b Scale, 500 μm. c Magnified view of pericytes from migrating edge of
scratch wound from conditions in a Scale bar, 100 μm
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confirmed our prior observations. These data indicate
that IFNγ may act to inhibit re-synthesis of PDGFRβ,
and therefore, block downstream signalling required for
proliferation and migration of pericytes after agonist-
induced activation of the receptor. Again, the same para-
digm was investigated in the presence of TNFα or IL-1β,
and although there was a trend towards a decrease in
PDGFRβ expression with either cytokine treatment, this
result was not significantly different from vehicle
treatment by either immunocytochemistry or western
blot analysis (Additional file 7: Figure S7).
To determine if the negative regulation of PDGFRβ by
IFNγ was acting at the translational or transcriptional
level, we investigated mRNA expression after PDGF-BB
treatment in the presence or absence of IFNγ. Although
PDGFRβ expression remained relatively stable over time
in the absence of the PDGF-BB, qRT-PCR revealed an
increase in PDGFRβ gene expression at 48 and 72 h
Fig. 7 Chronic IFNγ treatment reduces PDGFRβ re-synthesis following ligand-stimulated degradation. a–c Pericytes were treated for four consecutive
days (once every 24 h) with either vehicle (Veh) or IFNγ (1 ng/mL); the final 48 h was in the presence of either vehicle or PDGF-BB (10 ng/mL), with
representative images of PDGFRβ (green), αSMA (red), and Hoechst (blue) (a) Scale bar, 100 μm. Quantification of PDGFRβ (b) and αSMA (c) staining,
mean ± s.e.m. (n = 3), ####, ****(p < 0.0001), ***(p < 0.001), **(p < 0.01) (two-way ANOVA). d–f Pericytes were treated for three or four consecutive days
(once every 24 h) with either vehicle (Veh) or IFNγ (1 ng/mL). After 48 h, cells were treated with PDGF-BB (10 ng/mL) for either 24 or 48 h. Representative
blots of PDGFRβ, αSMA, and GAPDH (d) Quantification of band intensity of PDGFRβ (e) and αSMA (f), both normalized to GAPDH, mean ± s.e.m. (n= 3),
**(p< 0.01), *(p< 0.05) (two-way ANOVA). g–i Pericytes were pre-treated for 48 h (once every 24 h) with either vehicle or IFNγ (1 ng/mL) and then treated
with PDGF-BB (10 ng/mL) for 24, 48, 72, or 96 h (with IFNγ being added every 24 h throughout). qRT-PCR analysis of PDGFRβ (g), αSMA (h), and Ki67 (i)
transcripts was normalized to vehicle treatment and plotted as mean ± s.e.m. (n= 3), ####, ****(p< 0.0001), ##, **(p< 0.01), *(p< 0.05) (two-way ANOVA)
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post-PDGF-BB treatment in the presence of IFNγ,
although this was not statistically significant (Fig. 7g).
αSMA mRNA expression closely followed results from
protein analysis. αSMA expression was reduced by both
PDGF-BB and IFNγ treatment at all time points (Fig. 7h).
Ki67 was increased in response to PDGF-BB at both 24
and 48 h after stimulation, and this effect was blocked
by the presence of IFNγ (Fig. 7i). However, at 72 and
96 h after PDGF-BB treatment, no difference in prolifer-
ation is detected with IFNγ compared to vehicle. This is
most likely due to either cells reaching confluency in the
wells or saturation of the receptor signalling pathway.
Discussion
Pericytes are a vital component of brain microvasculature
and as such play an integral role in CNS homeostasis and
BBB function [61]. There is now very convincing evidence
that inflammation and an impaired BBB/BSCB can influ-
ence brain disease (reviewed [16, 62–64]). Previously, we
and others have identified brain pericytes as active partici-
pants in the inflammatory response by upregulating gene
and protein expression in response to inflammatory cues
[22, 26, 51]. Here, for the first time, we have shown that
chronic IFNγ modulates PDGFRβ pathway activation at
both the proximal and distal end of signal transduction
and thus impacts a crucial signalling pathway in human
brain pericytes. Pericytes cultured in the presence of IFNγ
for an extended period demonstrated increased mem-
brane expression of PDGFRβ, as well as ligand-stimulated
phosphorylation, and internalization. However, upon
ligand-induced downregulation, PDGFRβ protein levels
remained low, thereby reducing pericyte proliferation and
migration. In this manner, IFNγ interferes with a key as-
pect of pericyte biology. The potential impacts of such an
obstruction would be extremely detrimental to BBB
function in health and disease. Previous in-depth studies
have identified PDGF-BB and PDGFRβ as being necessary
for pericyte coverage of the BBB in the developing CNS
[27, 33]. Our data indicate that chronic IFNγ causes a
transient increase in PDGFRβ membrane expression
which therefore leads to an increase in ligand-induced re-
ceptor activation. This may be carried out through re-
localization of the PDGFRβ to specialized areas of the cell
(i.e., lipid rafts or non-rafts) that are differentially regu-
lated for distinct cellular outputs [65]. The cellular pur-
pose for this may be to maximize the responsiveness of
pericytes in conditions that would require proliferation or
migration, such as stroke [53, 66]. However, the presence
of IFNγ, as demonstrated in our model, would negatively
regulate this signal transduction.
Ultimately, elevated activation of the PDGFRβ by IFNγ
resulted in a dampened PDGF-BB-dependent prolifera-
tion response. The effects of IFNγ on proliferation have
been studied extensively and appear to be context and
cell-type dependent (reviewed [67]). Data presented here
identify a novel PDGF-BB-dependent mechanism for
IFNγ-mediated inhibition of proliferation, as cell num-
bers and proliferation markers were unchanged by
chronic IFNγ in the absence of PDGF-BB. Similarly,
knockdown of PDGFRβ in our cultured human brain
pericytes revealed a PDGF-BB-dependent block in prolif-
eration without reducing the basal proliferative state and
is supported by work in fibroblasts [68]. This is consist-
ent with our theory that IFNγ blocks PDGFRβ re-
synthesis, so that cells under chronic IFNγ conditions
essentially become PDGFRβ-depleted, but only after ini-
tial ligand-induced degradation. Moreover, since tran-
script levels of PDGFRβ are not reduced by IFNγ
treatment, this supports the conclusion that IFNγ modu-
lates PDGFRβ expression specifically at the protein level.
We also observed an effect of IFNγ on pericyte migra-
tion in a scratch wound assay. The negative influence on
cell migration was not specific to PDGF-BB-treated peri-
cytes; therefore, we cannot conclude that this is PDGF-
BB-dependent. In addition, since there was a block in
proliferation by IFNγ, this may in itself appear to inhibit
cell migration. However, previous studies of epithelial
cell migration in response to IFNγ treatment had re-
vealed modulation of cell focal adhesion proteins β1-
integrin and vinculin at the leading edge of migrating
cells [69]. This in turn resulted in a decreased rate of
wound closure with IFNγ treatment in a scratch wound
assay. Moreover, the differences in pericyte cell shape
observed under IFNγ conditions support the idea that
migration is also altered.
Our data suggest that chronic IFNγ modulates PDGFRβ
turnover after ligand stimulation and therefore inhibits
any subsequent receptor signalling. Indeed, degradation-
defective mutants of the PDGFRβ demonstrate increased
proliferation in response to ligand stimulation [60]. How-
ever, in addition to possible increases in receptor degrad-
ation, IFNγ may also cause inhibition of PDGFRβ protein
translation, which was observed after PDGF-BB treatment.
Compared to controls where PDGFRβ expression returns
after 48 h, with IFNγ treatment, this does not occur. This
phenomenon has not been previously investigated in re-
gard to PDGFRβ expression; however, IFNγ has been re-
cently shown to inhibit metabolism-related translation, in
order to upregulate inflammatory-response proteins in
macrophages [70]. In addition, TNFα and IL-1β were also
shown to reduce PDGFRβ expression in fibroblasts and
commercial pericytes; however, the mechanism behind
this was not identified [37, 51]. We have seen that chronic
treatment of primary human brain pericytes with either
TNFα or IL-1β resulted in a decrease in PDGFRβ protein
and mRNA expression (Additional file 1: Figure S1). This
result was consistent with previous work in commercial
human brain pericytes treated for 24 h with TNFα or IL-
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1β [51]. However, there was no change in PDGF-BB-
stimulated PDGFRβ internalization (Additional file 4:
Figure S4). And although PDGFRβ protein decreased
over time with TNFα or IL-1β treatment, by both mem-
brane and total PDGFRβ staining (Additional file 5:
Figure S5A, B), PDGFRβ protein degradation was not
significantly altered (Additional file 5: Figure S5C).
Moreover, PDGF-BB-induced pericyte proliferation in
the presence of TNFα or IL-1β was not different from
vehicle conditions; therefore, we focused on the specific
effects of IFNγ.
Nonetheless, the fact that individual cytokines can
alter PDGFRβ expression via unique mechanisms will be
important to consider when targeting this process in
pathology. Chronic inflammation generally constitutes
elevated concentrations of many cytokines, chemokines,
and other pro-inflammatory modulators over an ex-
tended period of time (months to years). As such, study-
ing the effects of a single cytokine alone has its
limitations, however, is important for dissection of path-
ways and identification of molecular targets. It will be
essential to also examine pericytes that have been ex-
posed to a multitude of pro-inflammatory cues, such as
those present in chronic inflammatory diseases. Now
that we have established the response of human brain
pericytes to both acute and chronic inflammatory cues,
we can begin to investigate the effects of combinations
of pro-inflammatory signals that are more representative
of physiology in chronic disease conditions.
Initial observations of chronic IFNγ on pericyte
markers revealed changes at the transcript level, curi-
ously, with opposing effects on PDGFRβ and αSMA. Al-
though PDGFRβ mRNA is constitutively expressed,
growth factor deprivation has been shown to increase
transcript levels [71]. Indeed, this is what we see in re-
sponse to chronic IFNγ treatment, indicating that this is
not dependent on stimulation with PDGF-BB.
The fact that IFNγ inhibits migration of pericytes both
in the presence and absence of PDGF-BB also implies a
PDGFRβ-independent mechanism. Our data also sug-
gests that IFNγ-mediated inhibition of αSMA expression
and migration is PDGF-independent and is in concord-
ance with previous studies in smooth muscle cells and
pericytes [72]. However, as there are a number of mem-
brane scaffolding and filament proteins that make up the
cytoskeletal machinery, IFNγ-mediated inhibition of
migration by pericytes likely involves additional factors
that have not been investigated here. In fact, modulation
of cytoskeletal and focal adhesion protein arrangement
has also been attributed to IFNγ-dependent migration
inhibition in endothelial cells [69]. Interestingly, TNFα
and IL-1β have also been shown to induce morpho-
logical changes in pericytes, namely a bipolar, linear
morphology, which may also have an impact on how
these cytokines can affect pericyte remodelling [73].
Therefore, alteration in cytoskeletal protein arrangement
may indeed contribute to impaired healing and remodel-
ling in response to injury leading to the leaky barrier
properties seen in brain disease.
PDGFRβ expression in brain pericytes is required for
BBB development and function [74]. However, this sig-
nalling pathway is also vital for the healing process in
the cerebral vasculature. Pericyte-specific activation of
PDGFRβ in response to either ischemia or traumatic
brain injury has been shown in rodent models to be im-
portant in wound healing [53, 75]. Moreover, PDGFRβ
deficiency resulted in increased infarct area, giving rise
to the conclusion that its expression may also provide
neuroprotection and contribute to more successful re-
covery [35, 66]. Interestingly, mice with PDGFRβ defi-
ciency demonstrated vascular leakage with no difference
in angiogenesis after ischemia, indicating that blood ves-
sels can form but have limited barrier capacity [66]. An
inability of pericytes to respond appropriately to PDGF-
BB released by endothelial cells after stress or injury
may have severe consequences. Although ischemia and
traumatic brain injury are extreme examples, many fac-
tors can contribute to more subtle BBB damage, such as
metabolic diseases (diabetes and obesity), genetics
(NOTCH3), and vascular risk factors [76–78]. These
small infractions accumulated over time in the presence
of a pro-inflammatory component would negatively
regulate the expression of PDGFRβ.
Inflammation has long been considered a contributor to
BBB breakdown, though the reasons for this have not been
clear. Now, we have evidence that not only pericytes play
an important role in transmitting the inflammatory re-
sponse by the expression of cytokines, chemokines, and cell
surface adhesion molecules but also the sustainability of
basic pericyte functions is vulnerable to chronic inflamma-
tory stress. In the case of IFNγ, attenuation of PDGF-BB
signalling through decreased PDGFRβ expression may re-
sult in a weakened response of pericytes; therefore, damage
to the BBB/BSCB would be left unrepaired. Investigations
of attenuated PDGFRβ and the effects on pericyte survival
and function in a whole animal context should be exam-
ined with an inducible knockout of PDGFRβ in brain
pericytes. However, studies using cultured human brain
pericytes can offer understanding of specific mechanistic
properties of pericyte function and help to identify molecu-
lar targets for improving pericyte survival and proliferation
under chronic inflammatory conditions. With these factors
considered, our in vitro results regarding PDGFRβ pathway
activation and protein expression may have profound impli-
cations for understanding pericyte dysfunction. Knowledge
of the exact mechanisms of this and how it may be modu-
lated pharmacologically would be beneficial for treatment
of disease where BBB impairment is present.
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Conclusions
PDGFRβ is critical for pericyte function but is reduced
in brain disorders that exhibit BBB and BSCB damage.
We have identified a mechanism by which chronic IFNγ
reduces pericyte signalling through the PDGFRβ path-
way and potentially BBB impairment in vascular-related
brain dysfunction.
Additional files
Additional file 1: Figure S1. Pericytes were treated for four consecutive
days (once every 24 h) with either vehicle (Veh), TNFα (5 ng/mL), or IL-1β
(1 ng/mL) as depicted in Fig. 1a. Cells were then fixed and total cells
counted from Hoechst labelled nuclei (A). The integrated intensity of the
staining PDGFRβ or αSMA staining was normalized to cell number (Hoechst)
and vehicle conditions (B,C), quantified from triplicate wells, and plotted as
mean ± s.e.m (n = 3), ***(p < 0.001), *(p < 0.05) (Student’s t test). (D, E) mRNA
from pericytes treated as in (A) was analysed by qRT-PCR. Inflammatory
target genes (IP-10, MCP-1, COX2, ICAM-1, CD74) (D) and pericyte marker and
proliferation marker genes (PDGFRβ, αSMA, and Ki67) (E) expression were
normalized to GAPDH and plotted as a fold change from vehicle (set to 1)
(2^ΔΔCT) ± s.e.m (n = 3), ****(p < 0.0001), ***(p < 0.001), **(p < 0.01), *(p <
0.05) by a Mann-Whitney, non-parametric test of ΔCT values. Note: Control
data are from the same experiments as Fig. 1. (TIF 1383 kb)
Additional file 2: Figure S2. Repeats of additional cases from Fig. 2: (A)
Pericytes were serum starved for 2 h and then treated with vehicle (lanes 1
and 7) or PDGF-BB (100 ng/mL) (lanes 2–6, and 8) for the indicated times and
analysed by SDS-PAGE as in Fig. 2. Representative blots from two additional
cases are shown. (B–F) Blots from (A) were analysed and quantified with
Image Studio™. Phosphorylated PDGFRβ (Tyr751) (p-PDGFRβ) (B), PDGFRβ (C),
and PDGF-BB (F) were normalized to GAPDH; phosphorylated Akt (Ser473)
(p-Akt) (D) and phosphorylated ERK (Tyr204) (p-ERK) (E) were normalized to
total Akt and ERK, respectively. (TIF 15997 kb)
Additional file 3: Figure S3. Repeats of additional cases from Fig. 3(b–e):
Pericytes were treated for four consecutive days (once every 24 h) with
either vehicle (Veh) or IFNγ (1 ng/mL). After 96 h total treatment, cells were
serum starved for 2 h and then treated with vehicle (−) or PDGF-BB
(100 ng/mL) for 30 min as in Fig. 3. (a, c) Representative western blots of
treated pericyte from two additional cases. (B, D) Bands were quantified with
Image Studio™ and normalized to vehicle control. p-PDGFRβ was normal-
ized to total PDGFRβ, and p-Akt and p-ERK were normalized to total Akt
and ERK, respectively. (TIF 2398 kb)
Additional file 4: Figure S4. Pericytes were treated for four consecutive
days (once every 24 h) with either vehicle (Veh), TNFα (5 ng/mL), or IL-1β
(1 ng/mL). After 96 h total treatment, cells were serum starved for 2 h and
then treated with vehicle (−) or PDGF-BB (100 ng/mL) for 30 min. PDGFRβ
puncta were quantified using MetaXpress™ software and normalized to cell
number and vehicle control and plotted as mean± s.e.m. (n= 3), ***(p< 0.001),
*(p < 0.05) (two-way ANOVA). Note: Control data are from the same
experiments as Fig. 3g. (TIF 723 kb)
Additional file 5: Figure S5. (A, B) Pericytes were treated for 24, 48, 72,
or 96 h (more cytokines added once every 24 h to appropriate wells)
with vehicle (Veh), TNFα (5 ng/mL), or IL-1β (1 ng/mL). Quantification of
total PDGFRβ (white bars) and membrane PDGFRβ (black bars) staining
intensity per cell from TNFα treated (A) or IL-1β treated (B) was normalized
to 0 h time point, plotted as mean ± s.e.m. (n = 2), *(p < 0.05) (ANOVA).
(TIF 1027 kb)
Additional file 6: Figure S6. Pericytes were treated for four consecutive
days (once every 24 h) with either vehicle (Veh), TNFα (5 ng/mL), or IL-1β
(1 ng/mL). After 48 h of cytokine treatment, cells were treated with either
vehicle or PDGF-BB (10 ng/mL) to measure the PDGF-BB-induced proliferative
response (A, B). This was done in two ways: after 96 h total treatment, cells
were fixed, labelled with a Ki67 antibody and Hoechst (A, C); alternatively, EdU
was added to measure cell proliferation over the final 24 h of the experiment
(B, C). Positive cells of the total cells measured by Hoechst were quantified
and plotted as mean ± s.e.m. (n= 3), ****(p< 0.0001), ***(p< 0.001), *(p< 0.05)
from a two-way ANOVA. (TIF 1034 kb)
Additional file 7: Figure S7. (A, B) Pericytes were treated for four
consecutive days (once every 24 h) with either vehicle (Veh), TNFα (5 ng/mL),
or IL-1β (1 ng/mL). After 48 h of cytokine treatment, cells were treated with
either vehicle or PDGF-BB (10 ng/mL) to measure PDGFRβ and αSMA
expression by immunocytochemistry. Quantification of PDGFRβ (A) and αSMA
(B) staining, mean ± s.e.m. (n= 3), ****(p< 0.0001), ***(p < 0.001), *(p< 0.05)
(two-way ANOVA). (C) Pericytes were treated for three or four consecutive
days (once every 24 h) with either vehicle (Veh), TNFα (5 ng/mL), or IL-1β
(1 ng/mL). After 48 h, cells were treated with PDGF-BB (10 ng/mL) for either
24 or 48 h. Western blot band intensity of PDGFRβ, αSMA, and GAPDH were
quantified, normalized to GAPDH, and plotted as mean ± s.e.m. (n= 3), and
differences were not significant (two-way ANOVA). (TIF 1163 kb)
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